NCT00894790

Brief Summary

This Study Will Evaluate Celecoxib Efficacy And Safety Versus Standard Doses Of Diclofenac In Acute Pain Due To Cervical Injury (Due To A Sprain) Related To A Motor Vehicle Accident

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
8

participants targeted

Target at below P25 for phase_4 pain

Timeline
Completed

Started Nov 2009

Shorter than P25 for phase_4 pain

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 27, 2009

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 7, 2009

Completed
6 months until next milestone

Study Start

First participant enrolled

November 1, 2009

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2010

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

February 25, 2011

Completed
Last Updated

February 2, 2021

Status Verified

January 1, 2021

Enrollment Period

2 months

First QC Date

March 27, 2009

Results QC Date

January 28, 2011

Last Update Submit

January 29, 2021

Conditions

Keywords

Treatment of the acute pain due to cervicalsprainCelecoxibNSAIDDiclofenac

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline to Day 7 of Participant's Assessment of Cervical Pain Due to Cervical Sprain

    Participant rated visual analogue scale (VAS) for pain ranging from 0 to 100 mm (no pain to worst possible pain).

    Baseline, Day 7

Secondary Outcomes (8)

  • Change From Baseline on VAS-pain at Day 3 and Day 14

    Baseline, Days 3, 14

  • Percentage of Participants With at Least a 20 mm Improvement on VAS-pain (Responder Rates)

    Baseline, Days 7, 14

  • Change From Baseline in Patient Global Assessment of Cervical Injury

    Baseline, Days 7, 14

  • Change From Baseline on Physician's Global Assessment of Cervical Injury

    Baseline, Days 7, 14

  • Change From Baseline in Modified Brief Pain Inventory-Short From (m-BPI-sf): Pain Interference Score

    Baseline, Days 7, 14

  • +3 more secondary outcomes

Study Arms (2)

1

EXPERIMENTAL
Drug: Celecoxib

2

ACTIVE COMPARATOR
Drug: oral Diclofenac

Interventions

celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg

1

diclofenac 75 mg tablet BID (twice a day)

2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients That Had Suffered A Car Accident And Due To It Suffered A Cervical Sprain

You may not qualify if:

  • Recent Cervical Sprains Or Other Cervical Conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Pfizer Investigational Site

México, D.F., 04500, Mexico

Location

Pfizer Investigational Site

México, D.F., 11510, Mexico

Location

Related Links

MeSH Terms

Conditions

PainSprains and Strains

Interventions

CelecoxibDiclofenac

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsWounds and Injuries

Intervention Hierarchy (Ancestors)

BenzenesulfonamidesSulfonamidesAmidesOrganic ChemicalsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsSulfonesSulfur CompoundsPyrazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPhenylacetatesAcids, CarbocyclicCarboxylic Acids

Results Point of Contact

Title
Pfizer ClinicalTrials.gov Call Center
Organization
Pfizer, Inc.

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 27, 2009

First Posted

May 7, 2009

Study Start

November 1, 2009

Primary Completion

January 1, 2010

Study Completion

January 1, 2010

Last Updated

February 2, 2021

Results First Posted

February 25, 2011

Record last verified: 2021-01

Locations